OCV Partners

Rad AI develops an artificial intelligence platform that automates report generation for radiologists. Its solution integrates with existing workflows, automating repetitive tasks to enhance efficiency, reduce burnout, and improve patient care.

Ossio is an orthopedic fixation company focused on transforming the fixation landscape with OSSIOfiber and intelligent bone regeneration technology. Its biocomposite hardware is designed to provide strong initial fixation for screws, pins, and plates while enabling bone regrowth so the implant is incorporated and ultimately replaced by natural bone. The platform aims to offer a biologically friendly alternative to permanent metal implants, reducing inflammation and avoiding residual hardware. Founded in 2014, Ossio’s approach combines a mineral fiber-reinforced biocomposite with techniques that support tissue regeneration, supporting surgeons in orthopedic and podiatric procedures and addressing patients and payors with a potentially improved healing trajectory and reduced need for future interventions.

Orca AI, founded in 2018 by a team of Navy veterans, is a maritime technology startup based in the United States. The company offers a comprehensive software solution that leverages artificial intelligence and computer vision to enhance safety, efficiency, and sustainability for shipping companies. Its platform detects, analyzes, and alerts users to dangerous scenarios in waterways and deep waters, significantly reducing the risk of collisions and human error. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed across various segments of the shipping industry. The platform is utilized by major industry players, including MSC, Seaspan, and NYK. With a workforce of 80 employees, Orca AI operates offices in London, Athens, Singapore, and Tel Aviv, and has raised a total of $38 million in funding over two rounds from venture capitalists in the United States, the United Kingdom, and Israel.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Rad AI develops an artificial intelligence platform that automates report generation for radiologists. Its solution integrates with existing workflows, automating repetitive tasks to enhance efficiency, reduce burnout, and improve patient care.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Ozette Technologies specializes in digitizing biological data using machine learning to provide a comprehensive view of an individual's immune system. This enables accelerated discovery and development of therapies and diagnostics.

Ockam Inc. provides a serverless platform for secure Internet-of-things (IoT) development. Its tool enables hardware-to-software interconnection, facilitates information exchange within connected systems, manages identities and cryptographic keys, optimizes connectivity, and connects application developers, engineers, and product managers.

Rad AI develops an artificial intelligence platform that automates report generation for radiologists. Its solution integrates with existing workflows, automating repetitive tasks to enhance efficiency, reduce burnout, and improve patient care.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Orca AI, founded in 2018 by a team of Navy veterans, is a maritime technology startup based in the United States. The company offers a comprehensive software solution that leverages artificial intelligence and computer vision to enhance safety, efficiency, and sustainability for shipping companies. Its platform detects, analyzes, and alerts users to dangerous scenarios in waterways and deep waters, significantly reducing the risk of collisions and human error. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed across various segments of the shipping industry. The platform is utilized by major industry players, including MSC, Seaspan, and NYK. With a workforce of 80 employees, Orca AI operates offices in London, Athens, Singapore, and Tel Aviv, and has raised a total of $38 million in funding over two rounds from venture capitalists in the United States, the United Kingdom, and Israel.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders marked by neuronal imbalance. Established in 2015 and headquartered in Cambridge, Massachusetts, the company leverages genetic insights to create innovative treatments for neurological and psychiatric conditions. Its leading product candidates include PRAX-114, an allosteric modulator targeting GABAA receptors, currently undergoing Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, along with PRAX-222, an antisense oligonucleotide aimed at treating patients with SCN2A epilepsy, and a program focused on KCNT1-related epilepsy. The company has established collaborations and licensing agreements with various organizations to enhance its research and development efforts.

SafeBreach Inc. is a cybersecurity company that specializes in breach and attack simulation (BAS). Founded in 2014 and headquartered in Sunnyvale, California, with an additional office in Tel Aviv, Israel, SafeBreach offers a platform designed to enhance an organization's security posture by simulating real-world attack methods. The platform utilizes a comprehensive Hacker's Playbook, which includes a range of breach techniques derived from actual cyber incidents, to proactively identify vulnerabilities within an enterprise's network, cloud, and endpoints. By mimicking the tactics of cybercriminals, SafeBreach enables businesses to validate their security controls and improve the responsiveness of their security operations center (SOC) analysts. The platform can integrate with various security information and event management systems, ticketing solutions, and automation tools, providing continuous visibility into potential security threats and allowing organizations to address issues before they can be exploited by attackers.

Founded in 2016, ByHeart is a New York-based company dedicated to producing evolved infant nutrition products. It translates leading scientific research into innovative foods and formulas that prioritize immune, microbiome, cognitive, and digestive health.

Finch Therapeutics is a biotechnology company based in Somerville, Massachusetts, focused on developing microbial therapies for patients with serious medical needs. The company specializes in creating microbiome-based treatments to address conditions driven by dysbiosis or disruption of the microbiome. Finch Therapeutics offers two main product platforms: Full-Spectrum Microbiota and Rationally-Selected Microbiota, which aim to restore microbiome functionality. These therapies are designed to treat various conditions, including recurrent C. difficile infection, chronic hepatitis B, inflammatory bowel disease, and gastrointestinal symptoms in children with autism. The company employs machine learning algorithms to analyze clinical data from successful fecal transplantations, identifying effective microbial combinations for therapeutic use. Finch Therapeutics was founded in 2017 and has a strong intellectual property portfolio, including over 70 issued patents relevant to microbiome therapeutics.

Figure8 Inc. is a New York-based company that operates a recreational facility focused on frozen dessert-themed attractions, games, and crafts. Founded in 2016 by Manish Vora and Maryellis Bunn, Figure8 aims to create engaging experiences that foster connections among individuals and with their surroundings. The company's mission is built on principles of imagination, connection, and creativity, emphasizing the importance of relationships in its offerings. Through its innovative approach, Figure8 seeks to provide unique entertainment experiences that resonate with a diverse audience.

Ossio is an orthopedic fixation company focused on transforming the fixation landscape with OSSIOfiber and intelligent bone regeneration technology. Its biocomposite hardware is designed to provide strong initial fixation for screws, pins, and plates while enabling bone regrowth so the implant is incorporated and ultimately replaced by natural bone. The platform aims to offer a biologically friendly alternative to permanent metal implants, reducing inflammation and avoiding residual hardware. Founded in 2014, Ossio’s approach combines a mineral fiber-reinforced biocomposite with techniques that support tissue regeneration, supporting surgeons in orthopedic and podiatric procedures and addressing patients and payors with a potentially improved healing trajectory and reduced need for future interventions.

Invoice2go is a technology company dedicated to simplifying the operational processes for small business owners and freelancers globally. The platform provides a comprehensive suite of tools that enable users to create professional invoices, manage appointments, track jobs, and accept various payment methods. By offering features such as expense tracking and reporting, Invoice2go helps users maintain organization and professionalism, ultimately aiding in business growth. Founded by a small business owner with a background in trades, the company has grown to serve over 210,000 users across more than 160 countries, facilitating the sending of $24 billion in invoices annually. Its teams, located in Redwood City, California, and Sydney, Australia, consist of professionals with experience from notable companies in the tech and finance sectors.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Orca AI, founded in 2018 by a team of Navy veterans, is a maritime technology startup based in the United States. The company offers a comprehensive software solution that leverages artificial intelligence and computer vision to enhance safety, efficiency, and sustainability for shipping companies. Its platform detects, analyzes, and alerts users to dangerous scenarios in waterways and deep waters, significantly reducing the risk of collisions and human error. By October 2024, Orca AI had secured bookings for 900 vessels, with 550 installations completed across various segments of the shipping industry. The platform is utilized by major industry players, including MSC, Seaspan, and NYK. With a workforce of 80 employees, Orca AI operates offices in London, Athens, Singapore, and Tel Aviv, and has raised a total of $38 million in funding over two rounds from venture capitalists in the United States, the United Kingdom, and Israel.